ArticlePloS one2021
Sarcopenia increases the risk of post-operative recurrence in patients with non-small cell lung cancer.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Association between sarcopenia and postoperative delirium in elderly surgical patients: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.Nutrients · 2023Pooled it
- Development and Validation of a Frailty Risk Prediction Model for Preoperative Non-Small-Cell Lung Cancer Patients: A Cross-Sectional Study.Annals of surgical oncology · 2026Article
- CT-derived thoracic muscle thickness is associated with prolonged hospitalization after video-assisted thoracoscopic surgery.Journal of thoracic disease · 2026Article
- The Interplay of Preoperative Sarcopenia, Systemic Inflammation, and Neoadjuvant Therapy in Resectable NSCLC-Identifying the Gap: A Narrative Review of Surgical and Oncological Outcomes.Medicina (Kaunas, Lithuania) · 2026Review
- Development and Validation of a Predictive Nomogram for Early Postoperative Recurrence in Non-Small Cell Lung Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Activin A is deeply involved in the progression of sarcopenia and leads to poor prognosis in lung cancer patients.Scientific reports · 2025Article
- Impact of Preoperative CT-Measured Sarcopenia on Clinical, Pathological, and Oncological Outcomes After Elective Rectal Cancer Surgery.Diagnostics (Basel, Switzerland) · 2025Article
- Effects of respiratory sarcopenia on the postoperative course in elderly lung cancer patient: a retrospective study.Journal of cardiothoracic surgery · 2025Article
- Increasing monocytes after lung cancer surgery triggers the outgrowth of distant metastases, causing recurrence.Cancer immunology, immunotherapy : CII · 2024Article
- Current status of research on sarcopenia in post-treatment cancer survivors in Japan:A narrative review.Fukushima journal of medical science · 2024Review
- Myostatin expression in lung cancer induces sarcopenia and promotes cancer progression.General thoracic and cardiovascular surgery · 2024Article
- Effect of sarcopenia and frailty on outcomes among patients with brain metastases.Journal of neuro-oncology · 2024Article
- The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance.Frontiers in pharmacology · 2024Review
- Long-term changes in psoas muscle mass after lobectomy and segmentectomy for early-stage lung cancer.Journal of cachexia, sarcopenia and muscle · 2023Article
- Skeletal muscle index is associated with long term outcomes after lobectomy for non-small cell lung cancer.BMC cancer · 2023Article
- Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- The process to overcome lung cancer sarcopenia.Journal of thoracic disease · 2023Article
- Measurement of sarcopenia in lung cancer inpatients and its association with frailty, nutritional risk, and malnutrition.Frontiers in nutrition · 2023Article
- Sarcopenia is associated with worse surgical complications but not relapse-free survival and overall survival in patients with retroperitoneal liposarcoma.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is among the most prevalent and serious cancer-related symptom, and is strongly correlated with a poor prognosis. Moreover, it reportedly predicts poor prognosis after surgery in patients with lung cancer. However, it is unclear whether sarcopenia directly affects post-operative recurrence. The purpose of this study was to evaluate whether sarcopenia can be a risk indicator for post-operative recurrence, and whether it suppresses anti-tumor immunity, in a cohort of patients with resected non-small cell lung cancer.
methodsThis study retrospectively reviewed the data of 256 consecutive patients who underwent curative lobectomy and lymph node dissection for non-small cell lung cancer at our institution. The psoas muscle mass index was calculated as the total psoas muscle area at the third lumbar vertebral level/height2 (cm2/m2). Sarcopenia was defined by a psoas muscle mass index of under 5.03 cm2/m2 and 3.17 cm2/m2 in male and female patients, respectively. Post-operative prognosis and cumulative incidence of recurrence rates were calculated.
resultsThe 5-year overall survival and disease-free survival rates post-surgery were 59.5% and 38.6%, respectively, in patients with sarcopenia versus 81.1% and 72.1%, respectively, in patients without sarcopenia (p < 0.001). The 5-year cumulative incidence of recurrence rate in patients with sarcopenia was significantly higher than those without sarcopenia (49.9% versus 22.4%, respectively) in every pathological stage. Pathological stages II and III (hazard ratio, 3.36; p = 0.004), histological type (hazard ratio, 2.31; p = 0.025), and sarcopenia (hazard ratio, 2.52; p = 0.001) were independent risk factors for post-operative recurrence according to multivariate analysis.
conclusionSarcopenia is a risk indicator for post-operative recurrence in patients with non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.